Comparison of Vivalan (viloxazine hydrochloride) with imipramine in the treatment of depression. A double-blind study.
Twenty-eight hospitalized patients with depressive illness entered a double-blind trial to compare viloxazine hydrochloride (Vivalan) with imipramine. Both drugs produced a statistically significant improvement in the depressive symptoms as early as the 7th day, measured by the HRS. A side effects check-list showed no significant difference between Vivalan and imipramine. A lack of anticholinergic effects was noted in the Vivalan group although upper gastro-intestinal side effects were more frequent. Two patients in the Vivalan group withdrew due to gastric symptoms.
D000275:Adjustment Disorders / Q000188:drug therapy; D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D003863:Depression / Q000188:drug therapy*; D004311:Double-Blind Method; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007099:Imipramine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009025:Morpholines / Q000627:therapeutic use*; D011581:Psychological Tests; D013997:Time Factors; D014745:Viloxazine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D009025:Morpholines; D014745:Viloxazine; D007099:Imipramine